NCT03867253View on ClinicalTrials.gov

Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

November 12, 2020

Study Completion Date

November 12, 2020

Conditions
Mild to Moderate Alzheimer's Disease
Interventions
DRUG

ORY-2001 Low dose

0.6mg ORY-2001 capsule

DRUG

ORY-2001 High dose

1.2mg ORY-2001 capsule

DRUG

Placebo

Placebo capsule

Trial Locations (4)

31909

Columbus Memory Center, Columbus

33414

Alzheimer's Research and Treatment Center, Wellington

191090

Abington Neurological Associates Ltd., Willow Grove

08540

Princeton Medical Institute, Princeton

Sponsors
All Listed Sponsors
collaborator

Alzheimer's Drug Discovery Foundation

OTHER

lead

Oryzon Genomics S.A.

INDUSTRY

NCT03867253 - Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease | Biotech Hunter | Biotech Hunter